Switching from Eliquis to Xarelto in Renal Impairment: Key Considerations

Critical Renal Function Thresholds

• The European Society of Cardiology recommends that switching from Eliquis (apixaban) to Xarelto (rivaroxaban) is generally contraindicated when CrCl is <30 mL/min and should be avoided or used with extreme caution when CrCl is 30-49 mL/min, as rivaroxaban carries higher bleeding risk and requires more renal clearance than apixaban 1, 2
• The American Heart Association notes that CrCl <30 mL/min is an FDA-labeled contraindication for rivaroxaban, and patients on hemodialysis should not receive rivaroxaban 2, 5
• The National Comprehensive Cancer Network recommends that rivaroxaban should be used with caution and dose reduction considered in patients with CrCl 30-49 mL/min 1, 6, 4

Pharmacokinetic Profile

• The European Heart Journal states that rivaroxaban has 66% renal excretion, making it highly dependent on kidney function, whereas apixaban has only 27% renal elimination, with predominantly hepatic metabolism 3, 4
• The Journal of the National Comprehensive Cancer Network notes that apixaban can be used down to CrCl 25 mL/min, though data below 25 mL/min are insufficient 2, 7, 5, 4

Bleeding Risk

• The European Heart Journal reports that rivaroxaban carries increased gastrointestinal bleeding risk compared to warfarin in patients ≥75 years with atrial fibrillation or venous thromboembolism 8, 1
• The Journal of the National Comprehensive Cancer Network states that rivaroxaban is associated with increased GI and genitourinary tract bleeding, and should be used with extreme caution in patients with GI lesions, pathology, or recent instrumentation 2, 7, 5

Monitoring Requirements

• The Journal of Thrombosis and Haemostasis recommends calculating baseline CrCl using the Cockcroft-Gault formula, and monitoring renal function 2-3 times per year in moderate renal impairment (CrCl 30-49 mL/min) 9, 10, 6
• The European Heart Journal suggests monitoring hepatic function periodically 8, 1

High-Risk Patient Populations

• The European Heart Journal notes that patients ≥75 years have increased gastrointestinal bleeding risk with rivaroxaban compared to warfarin, and elderly patients with concurrent renal impairment face compounded bleeding risk 8, 1
• The Journal of the National Comprehensive Cancer Network states that rivaroxaban should be used with caution in patients with GI pathology or recent instrumentation 2, 7, 5

Drug Interactions

• The Journal of Thrombosis and Haemostasis warns that combined P-gp and strong CYP3A4 inhibitors (ketoconazole, ritonavir) should avoid rivaroxaban entirely, and strong CYP3A4 inducers (rifampin, carbamazepine, phenytoin, St. John's wort) should also avoid rivaroxaban 9, 10